A deep dive into the oncology target PRMT5 with the CEO of Tango Therapeutics
- blonca9
- Oct 20, 2023
- 1 min read
Barbara Weber walks us through the science of PRMT5, shares her reaction to recent data, and describes how programs are designed differently.